Synthetic Oncolytic LNP-Replicon RNA for Cancer Immunotherapy
Exclusively Licensed
Invention type: Technology
/
Case number: #21306HJQ
The present disclosure relates to synthetic oncolytic viruses comprising a lipid nanoparticle comprising one or more types of lipid and a self-amplifying replicon RNA comprising a sequence that encodes an immunomodulatory molecule.
Researchers
Departments: David H Koch Institute for Integrative Cancer Res, Department of Biological Engineering, Department of Chemical Engineering
Technology Areas: Biotechnology: Synthetic Biology / Drug Delivery: Microparticles & Nanoparticles / Therapeutics: Nucleic Acids, Vaccines
Impact Areas: Healthy Living
-
synthetic oncolytic lnp-replicon rna and uses for cancer immunotherapy
Hong Kong | Published application -
synthetic oncolytic lnp-replicon rna for cancer immunotherapy
United States of America | Granted | 11,717,548 -
synthetic oncolytic lnp-replicon rna and uses for cancer immunotherapy
New Zealand | Pending -
synthetic oncolytic lnp-replicon rna uses for cancer immunotherapy
United States of America | Published application -
synthetic oncolytic lnp-replicon rna and uses for cancer immunotherapy
Malaysia | Pending -
synthetic oncolytic lnp-replicon rna and uses for cancer immunotherapy
Australia | Pending -
synthetic oncolytic lnp-replicon rna and uses for cancer immunotherapy
Brazil | Pending -
synthetic oncolytic lnp-replicon rna and uses for cancer immunotherapy
Canada | Published application -
synthetic oncolytic lnp-replicon rna and uses for cancer immunotherapy
China | Published application -
synthetic oncolytic lnp-replicon rna and uses for cancer immunotherapy
Colombia | Published application -
synthetic oncolytic lnp-replicon rna and uses for cancer immunotherapy
European Patent Convention | Published application -
synthetic oncolytic lnp-replicon rna and uses for cancer immunotherapy
Israel | Pending -
synthetic oncolytic lnp-replicon rna and uses for cancer immunotherapy
India | Published application -
synthetic oncolytic lnp-replicon rna and uses for cancer immunotherapy
Japan | Granted | 7,561,134 -
synthetic oncolytic lnp-replicon rna and uses for cancer immunotherapy
Mexico | Published application -
synthetic oncolytic lnp-replicon rna and uses for cancer immunotherapy
Malaysia | Granted | 0 -
synthetic oncolytic lnp-replicon rna and uses for cancer immunotherapy
New Zealand | Pending -
synthetic oncolytic lnp-replicon rna and uses for cancer immunotherapy
Philippines | Pending -
synthetic oncolytic lnp-replicon rna and uses for cancer immunotherapy
Russian Federation | Granted | 2,809,724 -
synthetic oncolytic lnp-replicon rna and uses for cancer immunotherapy
Saudi Arabia | Pending -
synthetic oncolytic lnp-replicon rna and uses for cancer immunotherapy
Singapore | Pending -
synthetic oncolytic lnp-replicon rna and uses for cancer immunotherapy
Thailand | Pending -
synthetic oncolytic lnp-replicon rna and uses for cancer immunotherapy
Korea (south) | Published application -
synthetic oncolytic lnp-replicon rna and uses for cancer immunotherapy
United Arab Emirates | Pending -
synthetic oncolytic lnp-replicon rna and uses for cancer immunotherapy
Japan | Published application
License this technology
Interested in this technology? Connect with our experienced licensing team to initiate the process.
Sign up for technology updates
Sign up now to receive the latest updates on cutting-edge technologies and innovations.